192 related articles for article (PubMed ID: 8758916)
21. Suramin inhibits vasoactive intestinal peptide (VIP) binding and VIP-induced cAMP accumulation into two human cancerous cell lines.
Bellan C; Pic P; Marvaldi J; Fantini J; Pichon J
Second Messengers Phosphoproteins; 1991; 13(4):163-71. PubMed ID: 1667418
[TBL] [Abstract][Full Text] [Related]
22. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.
Reubi JC; Läderach U; Waser B; Gebbers JO; Robberecht P; Laissue JA
Cancer Res; 2000 Jun; 60(11):3105-12. PubMed ID: 10850463
[TBL] [Abstract][Full Text] [Related]
23. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
[TBL] [Abstract][Full Text] [Related]
24. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor.
Xia M; Sreedharan SP; Bolin DR; Gaufo GO; Goetzl EJ
J Pharmacol Exp Ther; 1997 May; 281(2):629-33. PubMed ID: 9152366
[TBL] [Abstract][Full Text] [Related]
25. Effects of vasoactive intestinal peptide on adenosine 3',5'-monophosphate, ornithine decarboxylase, and cell growth in a human colon cell line.
Yu D; Seitz PK; Selvanayagam P; Rajaraman S; Townsend CM; Cooper CW
Endocrinology; 1992 Sep; 131(3):1188-94. PubMed ID: 1324153
[TBL] [Abstract][Full Text] [Related]
26. An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system.
Gozes I; McCune SK; Jacobson L; Warren D; Moody TW; Fridkin M; Brenneman DE
J Pharmacol Exp Ther; 1991 Jun; 257(3):959-66. PubMed ID: 1646331
[TBL] [Abstract][Full Text] [Related]
27. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
Sotomayor S; Carmena MJ; Schally AV; Varga JL; Sánchez-Chapado M; Prieto JC; Bajo AM
Int J Oncol; 2007 Nov; 31(5):1223-30. PubMed ID: 17912451
[TBL] [Abstract][Full Text] [Related]
28. The neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) modulate several biochemical pathways in human leukemic myeloid cells.
Hayez N; Harfi I; Lema-Kisoka R; Svoboda M; Corazza F; Sariban E
J Neuroimmunol; 2004 Apr; 149(1-2):167-81. PubMed ID: 15020077
[TBL] [Abstract][Full Text] [Related]
29. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
[TBL] [Abstract][Full Text] [Related]
30. Calcium signal-mediated expression of the vasoactive intestinal polypeptide gene and its small contribution to activity-dependent survival of mouse cerebellar granule cells.
Fukuchi M; Sakuragawa S; Tabuchi A; Tsuda M
J Neurosci Res; 2004 Jul; 77(1):26-34. PubMed ID: 15197736
[TBL] [Abstract][Full Text] [Related]
31. Importance of the vasoactive intestinal peptide receptor in the stimulation of cyclic adenosine 3',5'-monophosphate in gallbladder epithelial cells of man. Comparison with the guinea pig.
Dupont C; Broyart JP; Broer Y; Chenut B; Laburthe M; Rosselin G
J Clin Invest; 1981 Mar; 67(3):742-52. PubMed ID: 6259209
[TBL] [Abstract][Full Text] [Related]
32. Characterization of vasoactive intestinal peptide receptors on rat alveolar macrophages.
Sakakibara H; Shima K; Said SI
Am J Physiol; 1994 Sep; 267(3 Pt 1):L256-62. PubMed ID: 7943252
[TBL] [Abstract][Full Text] [Related]
33. The vasoactive intestinal peptide-receptor system is involved in human glioblastoma cell migration.
Cochaud S; Chevrier L; Meunier AC; Brillet T; Chadéneau C; Muller JM
Neuropeptides; 2010 Oct; 44(5):373-83. PubMed ID: 20638719
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of vasoactive intestinal peptide (VIP) binding on human melanoma cells IGR39 by nitric oxide: cGMP is not involved.
Fouchier F; Pichon J; Forget P
Eur J Cell Biol; 1994 Jun; 64(1):71-7. PubMed ID: 7957315
[TBL] [Abstract][Full Text] [Related]
35. Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells.
Gespach C; Bawab W; de Cremoux P; Calvo F
Cancer Res; 1988 Sep; 48(18):5079-83. PubMed ID: 2842044
[TBL] [Abstract][Full Text] [Related]
36. Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor.
Sreedharan SP; Patel DR; Huang JX; Goetzl EJ
Biochem Biophys Res Commun; 1993 Jun; 193(2):546-53. PubMed ID: 8390245
[TBL] [Abstract][Full Text] [Related]
37. Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation.
Vacas E; Fernández-Martínez AB; Bajo AM; Sánchez-Chapado M; Schally AV; Prieto JC; Carmena MJ
Biochim Biophys Acta; 2012 Oct; 1823(10):1676-85. PubMed ID: 22728770
[TBL] [Abstract][Full Text] [Related]
38. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.
Moody TW; Zia F; Draoui M; Brenneman DE; Fridkin M; Davidson A; Gozes I
Proc Natl Acad Sci U S A; 1993 May; 90(10):4345-9. PubMed ID: 8389448
[TBL] [Abstract][Full Text] [Related]
39. A vasoactive intestinal peptide antagonist inhibits the growth of glioblastoma cells.
Sharma A; Walters J; Gozes Y; Fridkin M; Brenneman D; Gozes I; Moody TW
J Mol Neurosci; 2001 Dec; 17(3):331-9. PubMed ID: 11859929
[TBL] [Abstract][Full Text] [Related]
40. (Arg15, Arg21) VIP: evaluation of biological activity and localization to breast cancer tumors.
Moody TW; Leyton J; Unsworth E; John C; Lang L; Eckelman WC
Peptides; 1998; 19(3):585-92. PubMed ID: 9533649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
